All News
RheumNow Live Preview (1.30.2026)
Dr. Jack Cush reviews the news and journal reports from RheumNow.com - and the top 5 reasons to attend RheumNow Live 2026, which is one week away.
Read Article
Aortitis in Giant Cell Arteritis Treated with Tocilizumab
The The Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group studied giant cell arteritis with aortitis, comparing the efficacy of intravenous vs. subcutaneously (SC) tocilizumab (TCZ) - demonstrating the superiority of SC TCZ.
Read Article
Retractions in Rheumatology
Retraction of rheumatology studies is not uncommon; a recent analysis shows retractions have risen substantially.
Read Article
Notch and TGFβ Signaling in Refractory Rheumatoid Arthritis
EurekAlert!
Spatial transcriptomic profiling of rheumatoid arthritis (RA) synovial biopsies (pre- and post-treatment) has revealed new insights into the pathobiology or treatment resistent RA.
Read Article
Clinical contributors to pathogenesis and treatment outcomes for rheumatoid arthritis. Full read review of pathogenesis and unmet needs in #RA https://t.co/IEC0tsp1Rk https://t.co/jIsqhy9rQh
Links:
Dr. John Cush RheumNow ( View Tweet)
Roche Canada announced that Health Canada has approved obinutuzumab (Gazyva) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy. Following four initial doses in the first year, Gazyva can be administered twice yearly https://t.co/P4dCVkoPCH
Dr. John Cush RheumNow ( View Tweet)
Testing for RF, CCP, ESR and CRP
Check out the accompanying Advanced Practice Rheum: Rheumatoid and Inflammation Testing video.
https://t.co/4hkDO1M2UD https://t.co/APRKYLAS3k
Dr. John Cush RheumNow ( View Tweet)
APPIPRA Study - Benefits of Early Treatment
Treating people who are at high risk of rheumatoid arthritis (RA) can delay the onset of the disease for several years, with benefits also continuing well after treatment has stopped.
https://t.co/GYguq7VlqT https://t.co/5Z0BXIm3cM
Dr. John Cush RheumNow ( View Tweet)
NEJM - Baker’s Cyst
A 63-year-old woman with psoriatic arthritis presented with a 9-month history of pain in the left knee. A nontender, palpable mass was present in the left popliteal fossa, which had a “speech bubble” shape on ultrasonography. https://t.co/7wBnkDoUaX https://t.co/m0AhRnDc4c
Links:
Dr. John Cush RheumNow ( View Tweet)
Expertise is valued by all, YET, (many consider) change might be risky. (happened w/ Hand-washing, antibiotics, smoking dangers, etc). "Just because the establishment doesn’t like it doesn’t mean it’s not a good idea. " - Seth Godin https://t.co/3vQ4eHa4jr https://t.co/9mIJwD1f7z
Dr. John Cush RheumNow ( View Tweet)
Remission? Single center study of 100 RA, 100 SLE pts assessed by SLEDAI-2K, SDAI, VAS. Remission/LDA found in 88% of 392 SLE visits & 91% of 389 RA visits(p=NS). Remission was more common in SLE vs RA (79% vs 69%; p= 0.0018). https://t.co/ZPRrYQMsCT
Dr. John Cush RheumNow ( View Tweet)
UK NHS has cut use of physician associates over ‘substitute doctor’ fear. The reduction in roles is being blamed by union leaders for an increasing in waiting times and consultants’ workload. Plus 76% of PAs said their scope of practice had been restricted in recent months. GMC https://t.co/i0l4x9UVhZ
Dr. John Cush RheumNow ( View Tweet)
Physical activity (PA) is assoc w/ reduced all-cause mortality in RA pts. Study of 1493 NHANES & 1724 UK Biobank RA cohorts showing robust inverse association between PA and all-cause mortality (HR: active = 0.48, highly active = 0.61) https://t.co/K6ALzqP3QQ https://t.co/2XJ0zD7FA3
Dr. John Cush RheumNow ( View Tweet)
PA Assn President position on DES/gov Proposed Rule on Federal Student Loans "... loan rule is deeply flawed, outside the Dept’s authority...inconsistent w/.. Trumps rural healthcare workforce priorities.. excluding PAs will decimate US healthcare workforce pipeline" https://t.co/p5owv3Ui2B
Dr. John Cush RheumNow ( View Tweet)
Electronic EHR reminders to deprescribe works! EHR study of 1146 pts(mean 74 yrs) showed 2 methods of E-reminder notifications resulted in either a 10.4% or 6.5% deprescribing (vs usual care); deprescribing was 40% more likely (RR 1.40; 95% CI, 1.14-1.73) https://t.co/sXnW5gUP0q https://t.co/n9LhUG612M
Dr. John Cush RheumNow ( View Tweet)
APP Survey Results: 2017 and 2025
https://t.co/UEfYsKL74u https://t.co/SYTA7OOOvV
Dr. John Cush RheumNow ( View Tweet)
Full read review of the Mechanistic Effects of Methotrexate in the Treatment of Rheumatoid Arthritis. https://t.co/PrMyZ7q3wX download here: https://t.co/fvEocwsXIv https://t.co/ZWVctochHV
Links:
Dr. John Cush RheumNow ( View Tweet)
B Cells at the Brink in Sjögren Disease
The current issue of Arthritis & Rheumatology reviews the current understanding of the immunopathogenesis of Sjögren disease (SjD) and how this understanding has informed drug development for this systemic autoimmune disorder. https://t.co/zI7lQ5N54o
Dr. John Cush RheumNow ( View Tweet)
Consensus on Managing Vertebral Fractures in Advanced CKD
A coalition of leading international experts has released the first comprehensive Consensus Statement on the Management of Vertebral Fractures in Chronic Kidney Disease (CKD) Stages G4–G5D. The statement highlights a https://t.co/gilX13EaUi
Dr. John Cush RheumNow ( View Tweet)
Japanese nationwide survey of 1943 RMD pts taking Azathioprine (AZA) 34% had adverse events: hepatobiliary (149%), GI (10%), blood/lymphatic (9%), infections (5%), & skin (2.4%). AEs lead to 71% D/C AZA. Serious AEs (Gr ≥3) higher w/ older (OR 2.5), & SLE (OR 2.3) https://t.co/lVNYVQATfx
Dr. John Cush RheumNow ( View Tweet)
